Clinical trials: Cancer Disease Progression
Prostate Cancer
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
This research is being done to test an investigational drug, called itraconazole, in the treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration (FDA) for the treatment of various fungal…
- Trial name
- NCT00887458
- Testing
- Itraconazole 200 mg, Itraconazole 300mg
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Johns Hopkins University
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant
This phase II trial studies how well lenalidomide works in treating patients with progressive or recurrent multiple myeloma after a donor stem cell transplant.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00619684
- Testing
- lenalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
In this phase I trial, patients with relapsed or refractory multiple myeloma will receive standard autologous stem cell transplant conditioned with high dose melphalan.
- Trial name
- BMT-03 (NCT02043847)
- Testing
- Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Prostate Cancer
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
The purpose of this study is to assess the effect of combining abiraterone with medicines that may block some of the ways that cells become resistant to abiraterone.
- Trial name
- NCT01828476
- Testing
- Abiraterone, ABT-263, Hydroxychloroquine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Rutgers, The State University of New Jersey
Moderate Epithelial Dysplasia, Mild Epithelial Dysplasia
Early Diagnosis of Oral Cancer by Detecting p16 Methylation
The purpose of this study is to verify the function of p16 methylation diagnostic reagents in early diagnosis of oral cancer.
- Trial name
- NCT01695018
- Volunteers
- 180 people
- Sponsor
- Peking University
Non-Melanomatous Skin Cancer
Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer
RATIONALE: A low-fat, balanced diet may prevent disease progression in patients with nonmelanomatous skin cancer. PURPOSE: Randomized phase II trial to study the effectiveness of a low-fat, balanced diet to prevent disease…
- Trial name
- NCT00003097
- Testing
- preventative dietary intervention
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Baylor College of Medicine
Acute Kidney Injury, Chronic Kidney Diseases
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e.
- Conditions
- Acute Kidney Injury, Chronic Kidney Diseases, Solid-organ Transplantation, Cancer
- Trial name
- NEPHROGENE2 (NCT05318196)
- Testing
- Biological samples collection
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- University Hospital, Toulouse
Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well…
- Trial name
- NCT07111520
- Testing
- BNT326, Pumitamig
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 880 people
- Sponsor
- BioNTech SE
Non Small Cell Lung Cancer
An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer
AZD9291 Early Access Program (EAP) was available in Taiwan during October 2015 to September 2016, a time period before the approval of AZD9291, to supply the unlicensed AZD9291 for the NSCLC patients who received at least one…
- Trial name
- NCT03457220
- Where
- 7 sites in Taiwan
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Glioblastoma
Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI
In this study, the invesigators look at how a new MRI technique (called amide proton transfer weighted (APTw) chemical exchange saturation transfer (CEST)) can improve treatment for brain tumors through early detection of tumor…
- Trial name
- GLIMPCE (NCT07121842)
- Testing
- Extended MRI
- Where
- 4 sites in Netherlands
- Volunteers
- 120 people
- Sponsor
- Erasmus Medical Center
Cancer
COMPASS: A Group ACT Program for Cancer Patients Treated at UCSF
Cancer Center Psychosocial services (Psycho-Oncology) offers group psychoeducational and behavioral programs as part of its clinical service for cancer patients and services at the Helen Diller Family Comprehensive Cancer Center.
- Trial name
- NCT04636346
- Testing
- Acceptance and Commitment Therapy, Questionnaires
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- University of California, San Francisco
Non-small Cell Lung Cancer
Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03654027
- Testing
- Anlotinib Plus Docetaxel, Docetaxel
- Volunteers
- 84 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Prostate Cancer
Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
Radium-223 is indicated for the treatment of patients with mCRPC with symptomatic bone metastases and no known visceral metastatic disease.
- Trial name
- EXCAAPE (NCT03002220)
- Testing
- radium-223
- Where
- 6 sites in Spain
- Volunteers
- 52 people
- Sponsor
- MedSIR
Metastatic Leiomyosarcoma
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
This is an open-label, multi-center, Phase II trial studying the combination of mocetinostat and gemcitabine in patients who have previously demonstrated disease progression either while, or within six months after, receiving…
- Trial name
- NCT02303262
- Testing
- Mocetinostat, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Oral Squamous Cell Carcinoma (OSCC)
Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma
This observational study will evaluate whether salivary interleukin-6 levels and selected interleukin gene polymorphisms are associated with regional lymph node involvement in patients with oral squamous cell carcinoma.
- Trial name
- IL6-OSCC (NCT07692360)
- Testing
- Saliva Collection and Biomarker Analysis
- Where
- 2 sites in Italy
- Volunteers
- 38 people
- Sponsor
- University of Pavia
Gastric Cancer
Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer
The purpose of this study is to evaluate the efficacy and overall survival of the regimen of XELOX (Xeloda and oxaliplatin combination) in the patients with relapsed and refractory gastric cancer.
- Trial name
- NCT00568529
- Testing
- Capecitabine and Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Liver Cancer
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00605722
- Testing
- bevacizumab (Avastin), erlotinib (Tarceva)
- Where
- 6 sites in Philippines, South Korea and 1 more
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
High-Grade Gliomas
Bevacizumab and Irinotecan to Treat Brain Tumors
Background: Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. It has shown activity against human brain tumors in laboratory tests and human clinical trials.
- Trial name
- NCT00393094
- Testing
- Bevacizumab, Irinotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
This phase II trial studies how well giving lenalidomide with or without rituximab works in treating patients with progressive or relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01419795
- Testing
- lenalidomide, rituximab, pharmacological study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostatic Neoplasms
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Primary Objective: Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: Describe treatment patterns Describe the characteristics and outcomes of patients…
- Trial name
- PORTREAT (NCT01076751)
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.